Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Therma Bright (THRM) has applied to Health Canada to conduct a clinical study for its AcuVid COVID-19 saliva test
  • The company is now focused on readying the trial site and personnel to begin the study
  • On March 16, 2021, the FDA announced new guidance to streamline the approval and use of rapid COVID-19 tests
  • The company believes its AcuVid COVID-19 saliva test complies with the new FDA guidance
  • Therma Bright is focused on providing consumers and medical professionals with quality medical devices
  • Therma Bright (THRM) is up 1.96 per cent and is currently trading at C$0.52 per share

Therma Bright (THRM) has applied to Health Canada to conduct a clinical study for its AcuVid COVID-19 saliva test.

The company is now focused on readying the trial site and personnel to begin the study once Health Canada grants its approval.

Rob Fia, Therma Bright’s CEO, commented,

“This is yet another significant milestone in moving our AcuVid test closer to market. We look forward to beginning the trial in Ontario, Canada as we explore other potential sites in the U.S., South America and Europe that will generate additional data to support our applications in those jurisdictions.”

On March 16, 2021, the FDA announced new guidance to streamline the approval and use of rapid COVID-19 tests.

Therma Bright believes AcuVid meets the new FDA guidance for test developers seeking emergency use authorization for serial testing.

Serial testing involves testing the same individual multiple times within a few days and can increase chances of detecting asymptomatic infection.

“This FDA action should positively impact the approval of our test in the U.S. and accelerate the acceptance and use of AcuVid, which is ideally suited for serial testing due to its ease of use and rapid results,” Fia added.

The company is not making any express or implied claims that its test product can eliminate or cure COVID-19 or the SARS-CoV-2 virus.

Therma Bright is focused on providing consumers and medical professionals with quality medical devices that address their unmet needs.

Therma Bright (THRM) is up 1.96 per cent and is currently trading at C$0.52 per share as of 9:41 am ET.

More From The Market Herald
Theratechnologies - Chief Medical Officer and Senior Vice President Dr. Christian Marsolais

" Theratechnologies (TSX:TH) confirms effectiveness of PDCs against vasculogenic mimicry

Theratechnologies (TH) reports its investigational peptide-drug conjugates (PDCs) are effective in inhibiting vasculogenic mimicry (VM) in ovarian and breast cancer models.

" Algernon Pharmaceuticals (CSE:AGN) receives $2M payment and applies for Nasdaq listing

Algernon Pharmaceuticals (AGN) has recently received a $2M cash payment from a refundable tax credit program for its clinical research work in Australia.

" MediPharm Labs (TSX:LABS) appoints new CEO

 MediPharm Labs (LABS) is pleased to announce that Bryan Howcroft will join MediPharm Labs as Chief Executive Officer and Director, effective November 15,

" Levitee Labs (CSE:LVT) enters into credit facility for up to $12 Million

Levitee Labs Inc. (LVT) has entered into a financing agreement for up to $12 million to fund further business expansion.